Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Catherine Zeta-Jones lawsuit

This article was originally published in The Rose Sheet

Executive Summary

Compaint filed on behalf of actress in Los Angeles federal court against French skin care marketer Caudalie, Neiman Marcus Group and Turnberry Associates claims companies used her name and persona to promote Caudalie products and services without authorization. Zeta-Jones alleges Caudalie and Neiman Marcus featured her name on promotional materials for Caudalie brand products and spas, complaint states. In addition, the Caudalie anti-aging/Vinotherapie Spa at Turnberry Place in Las Vegas unfairly ties its name and services to Zeta-Jones in promotional materials. Zeta-Jones has never used any of the skin care or other products or services provided by Caudalie, according to court document. Actress seeks general and special damages of no less than $5 mil., in addition to punitive and exemplary damages, permanent injunctive relief and expenses...

You may also be interested in...



Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel